Pfizer is the latest pharma heavyweight to get behind the promise of gene therapy, as the New York drugmaker has laid out plans to set up a dedicated R&D operation and signed a deal with startup Spark Therapeutics to kick-start the effort.
BlackBerry, maker of the Passport smartphone, and health analytics company NantHealth said they will launch a clinical genome browser early next year that will be HIPAA-compliant.
INC Research has deepened its partnership with the Society for Clinical Research Sites, supporting a training program and working to increase communication between trial sites and study investigators.
Catalent has signed a deal with Sellas to help the Swiss drugmaker develop an existing insomnia treatment for other central nervous system disorders.
Meda, a Swedish specialty pharma outfit, is scaling back its relationship with contract drug developer Recipharm, endangering jobs and putting a site at risk of closure.
Point-of-care diagnostics company Welch Allyn and visual electrophysiology player LKC Technologies have signed an exclusive partnership for the former to distribute the latter's RETeval DR device, which screens for diabetic retinopathy.
Seattle's Juno Therapeutics, at work on treatments that train the immune system to better fight cancer, has signed a deal to expand its pipeline of therapies, licensing a complementary candidate developed by the National Cancer Institute.
iRhythm has received a CE mark in Europe for its continuous heart monitoring Zio Service. The technology enables up to 14 days of continuous heart monitoring via a wireless patch; it includes analytical software, as well as report to the physician. In addition, iRhythm has partnered with cardiology distributor CardioLogic to market Zio in the U.K. for the diagnosis of atrial fibrillation and other cardiac arrhythmias.
Catalent has signed on with Concord, MA-based Valerion Therapeutics to help develop delivery technology for the company's line of orphan genetic treatments.
Recipharm has purchased a manufacturing facility from Flamel Technologies in Pessac, France, for $13.2 million. The move is part of an effort to incorporate drug delivery technologies into its contract development business.